Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Thromb Haemost. 2017 Feb;15(2):375–387. doi: 10.1111/jth.13579

Figure 4.

Figure 4

[A] Experimental design for antibody-induced thrombocytopenia in mice and subsequent tail bleeding studies, where [A1] dose-dependent depletion of platelets resulted in [A2] corresponding increase in bleeding time after tail-transection (10μg antibody cocktail dose resulted in ~90% platelet depletion and corresponding 4–5 fold increase in bleeding time compared to normal mice); [B] Severely thrombocytopenic (TCP) mice injected with PBS or control (unmodified) particles at various doses show no improvement (reduction) of bleeding time, but TCP mice injected with SynthoPlateTM vesicles show a dose-dependent significant improvement of bleeding time, with the highest dose (1000/nL, equivalent to normal murine platelet count) reducing the bleeding time to ~150 sec (close to bleeding time of ~100 sec for normal mice shown for comparison); ‘*’ indicates p ≤ 0.05, ‘**’ indicates p ≤ 0.01 and ‘***’ indicates p ≤ 0.001. NS: Not significant.